New York, New York (PRWEB) March 26, 2014
Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to move forward in a mass tort proceeding currently underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, the proceeding’s next meeting has been scheduled for April 4th at 2:00 p.m. Roughly 200 claims have been filed in the litigation on behalf of individuals who were allegedly harmed by the antipsychotic medication, including dozens that claim Risperdal caused gynecomastia (male breast growth) in men and boys. (Risperdal Litigation, case number 100300296)
“Our Firm hears from individuals seeking to file Risperdal gynecomastia claims on a regular basis. We are monitoring this proceeding very closely,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal.
Risperdal Gynecomastia Allegations
According to court documents, Risperdal is an atypical antipsychotic drug used to treat adult and adolescent schizophrenia, as well as bipolar disorder in adults and children ages 10-to-17. Risperdal is also approved to treat irritability in children (5-to-16 years of age) with autistic disorder. Among other things, plaintiffs in these lawsuits accuse Johnson & Johnson and its Janssen Pharmaceuticals unit of concealing side effects associated with the medication, including the link between Risperdal and gynecomastia. Plaintiffs further allege that the companies improperly marketed Risperdal for off-label uses, including the treatment of children long before pediatric indications were approved in 2006.
In November, Johnson & Johnson and Janssen agreed to pay $2.2 billion to resolve a lawsuit filed by the U.S. Department of Justice that accused the companies of improperly marketing Risperdal and other medications. Among other things, the government had accused the drug makers of engaging in off-label marketing of Risperdal, and of downplaying the drug’s potential to cause serious side effects, including diabetes and gynecomastia. According to the Justice Department, the settlement was the largest ever involving healthcare fraud in the nation’s history. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Men and boys who allegedly developed gynecomastia due to their use of Risperdal may be entitled to compensation for their injury-related damages. Learn more about filing a Risperdal lawsuit at Bernstein Liebhard LLP’s website. Free case reviews may also be obtained by calling the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com